Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

NCT03234465 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
200
Enrollment
INDUSTRY
Sponsor class

Stopped No efficacy could be demonstrated, sponsor decided to prematurely end the study.

Conditions

Interventions

Sponsor

Oragenics, Inc.